Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03885726 · ClinicalTrials.gov registry record · NA
HVNI Ambulation Feasibility Study
A NA study, sponsored by Vapotherm.
- Completed
- Registry status
- NA
- Development phase
- 32
- Enrollment target
NCT03885726: Completed NA study, sponsored by Vapotherm.
NCT03885726 is a NA study that has completed, run by Vapotherm. The registered enrollment target is 32 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03885726, a NA study, has completed, sponsored by Vapotherm.
- COMPLETED
- Registry status
- NA
- Development phase
- 32 participants
- Enrollment target
Study Summary
The pilot/feasibility study evaluates the ability of High Velocity Nasal Insufflation (HVNI) therapy to facilitate ambulation and mobilization in patients experiencing shortness of breath, as compared to simple oxygen therapy.
Primary Outcome
Defined as the distance of patient ambulation
Interventions
- DEVICE Precision Flow Plus
- DEVICE Treatment as Usual
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2018-11-21 |
| Est. Completion | 2019-03-11 |
| Phase | NA |
What the finished NCT03885726 record still lists
NCT03885726 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 32 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 2 interventions - of which Precision Flow Plus is the first listed.
NCT03885726 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03885726 about?
NCT03885726 is a clinical study titled "HVNI Ambulation Feasibility Study". The pilot/feasibility study evaluates the ability of High Velocity Nasal Insufflation (HVNI) therapy to facilitate ambulation and mobilization in patients experiencing shortness of breath, as compared to simple oxygen therapy.
What is the current status of trial NCT03885726?
This trial is currently completed. It is a NA study. The enrollment target is 32 participants. The study started on 2018-11-21. Estimated completion is 2019-03-11.
What interventions are being tested in trial NCT03885726?
The interventions under investigation include: Precision Flow Plus (DEVICE), Treatment as Usual (DEVICE).
Who is sponsoring clinical trial NCT03885726?
This trial is sponsored by Vapotherm, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03885726's enrollment target sits among peer trials
32 1578th of 2000 higher than 409 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02445781 · 32 participants · Early Phase 1
Differing Levels of Hypoglycemia
- NCT02792270 · 32 participants · NA
Caloric Restriction In Sarcoma Patients Treated With Pre-Operative RT
- NCT03068910 · 32 participants · Early Phase 1
Hyperandrogenemia and Altered Day-night LH Pulse Patterns
- NCT03208868 · 32 participants · NA
Leucine Enriched Essential Amino Acid Mixture to Reverse Muscle Loss in Cirrhosis
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI